The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

Tzu Fei Wang, Rohan Ahluwalia, Mark A. Fiala, Kathryn M. Trinkaus, Doug P. Cox, Matthew Jaenicke, Caitlin C. Moliske, Kenneth R. Carson, Tanya M. Wildes, Michael H. Tomasson, Keith E. Stockerl-Goldstein, Ravi Vlj

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of carfilzomib and pomalidomide on survival in this patient cohort. We retrospectively reviewed the records of 65 patients with dual refractory/intolerant myeloma diagnosed between January 2007 and May 2012 at a single institution. The median overall survival (OS) from the time patients became dual refractory/intolerant was 10.2 months. Patients who received carfilzomib or pomalidomide after they became dual refractory/intolerant had a better OS compared to those who did not (12.6 vs. 6.8 months, p = 0.03 by Wilcoxon test). Prospective randomized control trials are needed for confirmation.

Original languageEnglish
Pages (from-to)337-341
Number of pages5
JournalLeukemia and Lymphoma
Volume55
Issue number2
DOIs
StatePublished - Feb 2014

Keywords

  • Bortezomib
  • Carfilzomib
  • Lenalidomide
  • Multiple myeloma
  • Pomalidomide

Fingerprint

Dive into the research topics of 'The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide'. Together they form a unique fingerprint.

Cite this